Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study (THALASSA)

Novartis logo

Novartis

Status and phase

Completed
Phase 2

Conditions

Non-transfusion Dependent Thalassemia

Treatments

Drug: placebo
Drug: deferasirox

Study type

Interventional

Funder types

Industry

Identifiers

NCT00873041
EudraCT 2007-007000-15 (Registry Identifier)
CICL670A2209

Details and patient eligibility

About

CICL670A2209: This study will evaluate the safety and efficacy of deferasirox in non-transfusion dependent thalassemia patients with iron overload. Patients will be treated either with active treatment (deferasirox) or placebo for 12 months (core study phase). Patients who complete the core study phase will be offered to continue their study with the active treatment (deferasirox) in a 12 months extension phase. During the core and extension, the effects of treatment on iron overload in the liver will be evaluated using magnetic resonance imaging (MRI) assessments. CICL670A2209E1: A one-year open-label extension to a randomized, double-blind, placebo-controlled, phase II study to evaluate efficacy and safety of deferasirox in non-transfusion dependent thalassemia patients with iron overload (Thalassa).

Enrollment

166 patients

Sex

All

Ages

10+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Core Inclusion Criteria:

  • Male or female aged ≥ 10 years with non-transfusion dependent syndromes, not requiring transfusion within 6 months prior to study start. Note: there was a local country amendment for Greece only to change the age specific inclusion criteria to ≥ 18 years old
  • Liver iron concentration ≥ 5 mg/g dry weight measured by Magnetic resonance imaging (MRI) before study start
  • Serum ferritin >300 ng/mL at screening

Core Exclusion Criteria:

  • Hemoglobin S (HbS)-variants of thalassemia syndromes
  • Anticipated regular transfusion program during the study. Patients having a sporadic transfusion (e.g. in case of infection) throughout the study course will not be excluded
  • Any blood transfusion 6 months prior to study start
  • Creatinine clearance ≤ 60 mL/min at screening
  • Serum creatinine above the upper limit of normal at both screening visits
  • Significant proteinuria as indicated by a urine protein/urine creatinine ratio > 1.0 mg/mg
  • Alanine aminotransferase (ALT) of > 5 x the upper limit of normal at both screening visits
  • Concomitant therapy with hydroxyurea, erythropoietin, butyrate
  • History of deferasirox treatment
  • Pediatric patients: a patient's weight of below 20 kg

Extension Inclusion Criteria:

  • Patients who completed the core CICL670A2209 clinical trial
  • Written informed consent obtained prior entry to one year extension study CICL670A2209

Extension Exclusion Criteria:

  • Patients with a continuous increase in serum creatinine ≥ 33% above the baseline value and > ULN who did not improve after drug interruption or dose reduction in the core study
  • Patients with a continuous increase in ALT greater than 2 times the baseline value and > 5 times ULN who did not improve after drug interruption or dose reduction in the core study
  • Patients with progressive proteinuria, as assessed by the investigator, who did not improve after drug interruption or dose reduction in the core study
  • Significant medical condition interfering with the ability to partake in this study (e.g.systemic uncontrolled hypertension, unstable cardiac disease not controlled by standard medical therapy, systemic disease (cardiovascular, renal, hepatic, etc.)

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

166 participants in 4 patient groups, including a placebo group

5 mg/kg/day deferasirox
Experimental group
Description:
Participants received a starting dose of 5 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
Treatment:
Drug: deferasirox
Drug: placebo
10 mg/kg/day deferasirox
Experimental group
Description:
Participants received a starting dose of 10 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
Treatment:
Drug: deferasirox
Drug: placebo
5 mg/kg/day placebo
Placebo Comparator group
Description:
Placebo tablet matching 5 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
Treatment:
Drug: placebo
10 mg/kg/day placebo
Placebo Comparator group
Description:
Placebo tablet matching 10 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
Treatment:
Drug: placebo

Trial contacts and locations

21

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems